Proposed Policy #1: Require inert placebos to evaluate vaccine safety
In the world of pharmaceutical drugs, controlled trials are considered the “gold standard” by which to evaluate safety and efficacy. The way it works is simple: the experimental group receives the drug, while a control group receives a placebo – an inert substance (e.g. sugar pill). After the trial is over, health outcomes are compared between the experimental group and the control group. If the drug is found to be safe and effective, it is allowed onto the market.
According to the Centers for Disease Control and Prevention (CDC): “Before vaccines are approved by the Food and Drug Administration (FDA), they are tested extensively by scientists to ensure they are effective and safe.” That sounds fine in theory, but what the CDC fails to mention is that clinical trials used to evaluate vaccine safety are not required to use inert placebos (i.e. saline injections) in their control group. Instead, the experimental (vaccine) group is compared to a “placebo” group that typically receives either another vaccine, or aluminum adjuvant (a known neurotoxin). This makes it nearly impossible to scientifically determine the true safety profile of a vaccine. Requiring inert (saline) placebos in clinical trials used to assess vaccine safety would solve this problem.
Proposed Policy #2: Automate the Vaccine Adverse Event Reporting System (VAERS)
The Vaccine Adverse Events Reporting System (VAERS) is a passive surveillance system designed to capture vaccine adverse events once a vaccine has been put onto the market. Unfortunately, fewer than 1% of vaccine adverse events are reported to VAERS.
“Public and professional confidence in vaccination depends on reliable post marketing surveillance systems to ensure that rare and unexpected adverse effects are rapidly identified.”
An attempt to create an automated system to facilitate detection and clinician reporting of vaccine adverse events, in order to improve the safety of national vaccination programs, found that 1.4 million doses (of 45 different vaccines) given to 376,452 individuals resulted in 35,570 possible reactions. In other words, 2.6% of vaccinations given may have resulted in an adverse reaction. The team behind this project concluded that it is possible to automatically detect adverse events in defined ways, and to electronically report them to VAERS. Automating VAERS with electronic support would yield more meaningful data on the safety profile of vaccines.
Proposed Policy #3: Compare health outcomes of vaccinated vs. unvaccinated populations
It is widely accepted that vaccines are effective at protecting against the infectious diseases they are intended to prevent. Despite this benefit, the possibility exists that vaccines may also have “non-specific effects” that could potentially increase the risk of negative health outcomes and all-cause mortality.
In 2017, a first-of-its-kind pilot study done in the United States comparing the health outcomes of completely unvaccinated children to fully vaccinated children found that the unvaccinated children had higher rates of chickenpox and pertussis (whooping cough). The fully vaccinated children, on the other hand, had higher rates of chronic disease, neurodevelopmental disorders, and allergies.
Since then, additional peer-reviewed studies comparing the health outcomes of vaccinated vs. unvaccinated children have found that vaccinated children are more likely than unvaccinated children to have chronic health conditions such as: ADHD, autism, allergies, asthma, etc. https://www.gutresolution.com/the-overmedication-of-our-children/
Proposed Policy #4: Make vaccine manufacturers liable for vaccine injuries
In 1986, Congress passed the National Childhood Vaccine Injury Act which shielded pharmaceutical companies from lawsuits for injuries and deaths caused by vaccines. Since 1988, over $4 billion dollars of taxpayer money has been used to compensate those injured or killed by vaccines through the Vaccine Injury Compensation Program – a federal program that has taken on vaccine liability for the pharmaceutical industry.
Today in the United States, most vaccines are essentially liability-free products for the pharmaceutical industry that manufacturers them. If consumers are unable to sue for injuries and deaths caused by vaccines, then there is little financial incentive for pharmaceutical companies to create safer vaccines.
Making pharmaceutical companies liable for injuries and deaths caused by vaccines acts as a natural check and balance, ensuring the safety of a pharmaceutical product manufactured by the least trusted industry in the United States.